Modulation of myeloid and T cells in vivo by Bruton's tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma

Ibrutinib Single-handedly Impacts Immune Environment in Metastatic PDAC

Immunologic Strategies in Pancreatic Cancer: Making Cold Tumors Hot

Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective

Modulation of myeloid and T cells in vivo by Bruton's tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma

T cells infiltrate PDA regardless of GM-CSF expression. A-C) IHC of

Frontiers Chimeric Antigen Receptor T-Cells: An Overview of Concepts, Applications, Limitations, and Proposed Solutions

Li Zhang, PhD UCSF Global Cancer Program

Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer

The recent progress of myeloid‐derived suppressor cell and its targeted therapies in cancers - Ren - 2023 - MedComm - Wiley Online Library

M1 Macrophage-Derived Nanovesicles Potentiate the Anticancer Efficacy of Immune Checkpoint Inhibitors

Scientific rationale for integrative and personalised strategies for pancreatic ductal adenocarcinoma management

WO2016087994A1 - Btk inhibitors to treat solid tumors through modulation of the tumor microenvironment - Google Patents

The reciprocal regulation between host tissue and immune cells in pancreatic ductal adenocarcinoma: new insights and therapeutic implications, Molecular Cancer

Cancers, Free Full-Text